Supplementary Table S2 from Nucleophosmin Plays a Role in Repairing DNA Damage and Is a Target for Cancer Treatment

Supplementary Table S2 from Nucleophosmin Plays a Role in Repairing DNA Damage and Is a Target for Cancer Treatment

<p>The relationship between NPM1 dependency and cell line metastatic propensity, determined from genome-wide CRISPR-Cas9 screens (https://depmap.org/portal/interactive). A score of zero indicates that a gene is not essential. Common essential genes have a median score of -1. A lower score indi...

Descripció completa

Guardat en:

Dades bibliogràfiques
Autor principal:	Konjeti R. Sekhar (15400345) (author)
Altres autors:	Michael L. Freeman (15400348) (author)
Publicat:	2025
Matèries:	Cancer Molecular and Cellular Biology Therapeutic Research and Development DNA Damage and Repair Genomic instability Small Molecule Agents
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars

Supplementary Table S1 from Nucleophosmin Plays a Role in Repairing DNA Damage and Is a Target for Cancer Treatment
per: Konjeti R. Sekhar (15400345)
Publicat: (2025)

Supplementary Table S1 from G-Quadruplex Structures Are Key Modulators of Somatic Structural Variants in Cancers
per: Rongxin Zhang (15293341)
Publicat: (2025)

Supplementary Table S2 from G-Quadruplex Structures Are Key Modulators of Somatic Structural Variants in Cancers
per: Rongxin Zhang (15293341)
Publicat: (2025)

Figure 1 from Cancer-Associated SF3B1 Mutations Confer a BRCA-Like Cellular Phenotype and Synthetic Lethality to PARP Inhibitors
per: Katrina M. Lappin (9340394)
Publicat: (2025)

Figure 2 from Cancer-Associated SF3B1 Mutations Confer a BRCA-Like Cellular Phenotype and Synthetic Lethality to PARP Inhibitors
per: Katrina M. Lappin (9340394)
Publicat: (2025)

Figure 3 from Cancer-Associated SF3B1 Mutations Confer a BRCA-Like Cellular Phenotype and Synthetic Lethality to PARP Inhibitors
per: Katrina M. Lappin (9340394)
Publicat: (2025)

Figure 4 from Cancer-Associated SF3B1 Mutations Confer a BRCA-Like Cellular Phenotype and Synthetic Lethality to PARP Inhibitors
per: Katrina M. Lappin (9340394)
Publicat: (2025)

Supplementary Table S2 from Clinical Relevance of <i>BRCA1</i> Promoter Methylation Testing in Patients with Ovarian Cancer
per: Félix Blanc-Durand (15049400)
Publicat: (2025)

Supplementary Data from SENP1 Decreases RNF168 Phase Separation to Promote DNA Damage Repair and Drug Resistance in Colon Cancer
per: Min Wei (16918572)
Publicat: (2025)

Supplementary Data from SENP1 Decreases RNF168 Phase Separation to Promote DNA Damage Repair and Drug Resistance in Colon Cancer
per: Min Wei (16918572)
Publicat: (2025)

Table 1_Mechanistic study of TFE3 breakage in TFE3-rearranged renal cell carcinoma: the perspective of non-canonical DNA structures and their stability.docx
per: Xiaopo Zhang (402895)
Publicat: (2025)

Supplementary Table S2 from Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma
per: Arun Kanakkanthara (14937731)
Publicat: (2025)

Supplementary Table S3 from Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma
per: Arun Kanakkanthara (14937731)
Publicat: (2025)

Deletion of the C-terminus of ATR leads to DNA damage and an increase of aberrant cells.
per: Gabriel L. A. da Silva (22676649)
Publicat: (2025)

Supplementary Data from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
per: Long Jiang (14956159)
Publicat: (2025)

Supplementary Data from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
per: Long Jiang (14956159)
Publicat: (2025)

Supplementary Table from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
per: Long Jiang (14956159)
Publicat: (2025)

Supplementary Tables S1-S11 from <i>NBN</i> Pathogenic Germline Variants are Associated with Pan-Cancer Susceptibility and <i>In Vitro</i> DNA Damage Response Defects
per: Sami Belhadj (15052341)
Publicat: (2025)

Supplementary Table S2 from Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727)
per: Holly Tovey (16824233)
Publicat: (2025)

Supplementary Table S3 from Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727)
per: Holly Tovey (16824233)
Publicat: (2025)

Table S1 from TONSL Is an Immortalizing Oncogene and a Therapeutic Target in Breast Cancer
per: Aditi S. Khatpe (15293176)
Publicat: (2025)

Table S10 from TONSL Is an Immortalizing Oncogene and a Therapeutic Target in Breast Cancer
per: Aditi S. Khatpe (15293176)
Publicat: (2025)

Table S11 from TONSL Is an Immortalizing Oncogene and a Therapeutic Target in Breast Cancer
per: Aditi S. Khatpe (15293176)
Publicat: (2025)

Table S12 from TONSL Is an Immortalizing Oncogene and a Therapeutic Target in Breast Cancer
per: Aditi S. Khatpe (15293176)
Publicat: (2025)

Table S13 from TONSL Is an Immortalizing Oncogene and a Therapeutic Target in Breast Cancer
per: Aditi S. Khatpe (15293176)
Publicat: (2025)

Table S14 from TONSL Is an Immortalizing Oncogene and a Therapeutic Target in Breast Cancer
per: Aditi S. Khatpe (15293176)
Publicat: (2025)

Table S15 from TONSL Is an Immortalizing Oncogene and a Therapeutic Target in Breast Cancer
per: Aditi S. Khatpe (15293176)
Publicat: (2025)

Table S2 from TONSL Is an Immortalizing Oncogene and a Therapeutic Target in Breast Cancer
per: Aditi S. Khatpe (15293176)
Publicat: (2025)

Table S3 from TONSL Is an Immortalizing Oncogene and a Therapeutic Target in Breast Cancer
per: Aditi S. Khatpe (15293176)
Publicat: (2025)

Table S4 from TONSL Is an Immortalizing Oncogene and a Therapeutic Target in Breast Cancer
per: Aditi S. Khatpe (15293176)
Publicat: (2025)

Table S9 from TONSL Is an Immortalizing Oncogene and a Therapeutic Target in Breast Cancer
per: Aditi S. Khatpe (15293176)
Publicat: (2025)

Supplemental Table 1 from Polymorphisms in the Nonhomologous End-joining DNA Repair Pathway are Associated with HPV Integration in Cervical Dysplasia
per: Jennifer M. Geris (16426277)
Publicat: (2025)

Figure 1 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
per: Gonzalo Rodriguez-Berriguete (15056057)
Publicat: (2025)

Figure 2 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
per: Gonzalo Rodriguez-Berriguete (15056057)
Publicat: (2025)

Figure 3 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
per: Gonzalo Rodriguez-Berriguete (15056057)
Publicat: (2025)

Figure 4 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
per: Gonzalo Rodriguez-Berriguete (15056057)
Publicat: (2025)

Figure 5 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
per: Gonzalo Rodriguez-Berriguete (15056057)
Publicat: (2025)

Supplementary Table S1 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
per: Gonzalo Rodriguez-Berriguete (15056057)
Publicat: (2025)

Table S1 from ENIGMA <i>CHEK2</i>gether Project: A Comprehensive Study Identifies Functionally Impaired <i>CHEK2</i> Germline Missense Variants Associated with Increased Breast Cancer Risk
per: Lenka Stolarova (16547259)
Publicat: (2025)

Table S2 from ENIGMA <i>CHEK2</i>gether Project: A Comprehensive Study Identifies Functionally Impaired <i>CHEK2</i> Germline Missense Variants Associated with Increased Breast Cancer Risk
per: Lenka Stolarova (16547259)
Publicat: (2025)

Cannot write session to /tmp/vufind_sessions/sess_ile7ioupu7cd54jfpbobnm9hcd